Abstract

VILLARREAL RIOS, Enrique et al. Cost effectiveness of the use of pharmacological treatment regimens in patients diagnosed with type 1 Diabetes Mellitus. Rev Clin Med Fam [online]. 2012, vol.5, n.3, pp.158-165. ISSN 2386-8201.  https://dx.doi.org/10.4321/S1699-695X2012000300003.

Objective: To determine the evaluation cost effectiveness of the schemes of pharmacologic therapy in the diabetic patient.  Design: Cost-effectiveness Location: Familiar Medicine Units 9, 13 and 16 of the Mexican Institute of the Social Insurance of the city of Querétaro Participants: Patients with diagnosis of diabetes mellitus type 2, with time of diagnosis between one and five years Main measurements: Three groups of 30 patients integrated themselves each one: Group 1: Pharmacologic treatment with metformina and insulin NPH; Group 2: Pharmacologic treatment with glibenclamida and metformina; Group 3: Pharmacologic treatment with metformina. The technical sample was by quota, was used as frame sample the listings of patients with diabetes in the familiar medicine units. The studied variables included to characteristics sociodemographics, of health, cost of the use of the services (medicine familiar, to laboratory and pharmacia); and effectiveness (glycaemia smaller average to 130 mg/dl). For statistical analysis was used percentage, averages and scenes for cost-effectiveness Results: In all the scenes the highest effectiveness corresponds to the metformina scheme, the effectiveness fluctuates between 48.3% and 100.0%. The annual average of consultations in familiar medicine is highest in the scheme of glibenclamida and metformina (10.0). The highest cost corresponds to the scheme glibenclamida and metformina (€173.6). In the scene of 130 mg/dl the best relation cost effectiveness appears in the metformina scheme, to obtain the 100% of effectiveness has a cost of €1,657 in scheme insulin and metformina, euros695 in the scheme glibenclamida and metformina, and e334 in scheme metformina Conclusion: Best relation cost effectiveness corresponds to the metformina scheme.

Keywords : Diabetes mellitus type 2; Metformina; Glibenclamida; Insulin; Treatment; Cost-effectiveness.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )